As of March 6, 2019, nine of fifteen sites are officially screening for our Phase 3 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Study volunteers will be administered …
On February 5, 2019, a MAPS-sponsored Phase 3 study site for MDMA-assisted psychotherapy for PTSD was initiated in Be’er Ya’akov, Israel. Led by Principal Investigator Jana Yakirevitch, M.D., this …
On February 3, 2019, the Israeli Ministry of Health announced the approval of compassionate use for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which will allow 50 patients to …
This month, our Phase 3 multi-site study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is continuing to open sites for screening. Eight sites are open for screening at this time. …
This month, MAPS study sites in New Orleans, Louisiana, Charleston, South Carolina, Fort Collins, and Boulder, Colorado received a shipment of pharmaceutical-grade MDMA, made under current Good Manufacturing …
Our FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD have officially launched. These trials are taking place at 14 locations across the United States, Canada, and Israel. On …
MAPS-sponsored researchers have completed study initiation visits for FDA-regulated Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at five United States locations: …
As summer comes to a close, we will begin the process of screening applications and enrolling participants for FDA-regulated Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder …
On June 12, 2018, MAPS had a successful meeting in London, United Kingdom, with the Scientific Advice Working Party (SAWP) of the European Medicines Agency (EMA). The discussion focused on scientific advice …
A Phase 3 Program of MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder (PTSD) Two Trials: MAPP1 and MAPP2 Study Sponsor: MAPS, a 501(c)(3) non-profit research organization …
On August 16, 2017, the FDA granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. The FDA grants this designation for treatments that (1) are intended alone or in combination with …
On June 22, 2017, MAPS submitted to the U.S. Food and Drug Administration (FDA) an application for Breakthrough Therapy designation for our upcoming Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic …
